Long acting GLP-1 receptor agonist (injectable)
Exenimp implant
EXENIMP_IMPLANT
Doses in this pooled treatment
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.96 (0.09 to 79.31) | 0.36 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 4.38 (1.73 to 11.45) | 0.23 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 5.93 (1.62 to 24.99) | 0.21 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.28 (0.64 to 9.84) | 0.32 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 5.46 (1.00 to 47.37) | 0.14 |